How Has The Diabetic Kidney Disease Market Size Evolved In Recent Years?
The diabetic kidney disease market has seen considerable growth due to a variety of factors.
• The market size for diabetic kidney disease has exhibited substantial growth in the past few years. It is projected to expand from $2.67 billion in 2024 to $2.81 billion in 2025, with a compound annual growth rate (CAGR) of 5.2%. Factors such as better awareness of diabetes-related complications, advancements in diagnostic methodologies, the creation of ace inhibitors and arbs, clinical examination and treatment strategies, and the establishment of guideline and disease control protocols have contributed to this growth during the historical period.
What Does Future Hold for The Diabetic Kidney Disease Market By 2029?
The Diabetic Kidney Disease market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market for diabetic kidney disease is projected to witness robust expansion. It is forecasted to reach a valuation of $3.56 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.1%.
Personalized medical treatments and biomarker advancements, an increasing worldwide prevalence of diabetes, emphasis on modifying disease therapies, remote healthcare, and modifications in health policies and reimbursement are among the influential factors attributing to this growth in the forecast period. The trending aspects during this period are expected to encompass improvements in renal replacement therapies, precision medicine methodologies, an emphasis on early detection and diagnosis, advancing therapeutics, and a rise in the management of concurrent health conditions.
What Are The Primary Growth Drivers In The Diabetic Kidney Disease Market?
The diabetic kidney disease market is anticipated to expand due to the increasing incidence of chronic kidney disease (CKD). CKD is a long-term condition that gradually leads to a loss of kidney function, causing complications including high blood pressure, anemia, and bone diseases. The need for diagnosis and treatment options for CKD further drives the growth of the diabetic kidney disease market. For example, Kidney Research UK, a significant UK charity, reported in June 2023 that roughly 7.2 million individuals, or more than 10% of the population in the UK, suffer from CKD. Of this number, 3.25 million are in the most severe stages and about 3.9 million are in the early stages, which are often asymptomatic and untreated. It is predicted that by 2033, the total number of people with chronic kidney disease in the UK could rise to 7.61 million. Consequently, the escalating prevalence of CKD is propelling the diabetic kidney disease market growth.
What Is The Segmentation Of The Global Diabetic Kidney Disease Market?
The diabetic kidney disease market covered in this report is segmented –
1) By Type: Type 1 Diabetes, Type 2 Diabetes
2) By Treatment: Angiotensin Receptor Blockers (Arbs), Angiotensin-Converting Enzyme (Ace) Inhibitors, Antioxidant Inflammation Modulator, Calcium Channel Blockers, Other Treatments
3) By End User: Hospitals, Homecare, Specialty Centers, Other End Users
Subsegments:
1) By Type 1 Diabetes: Autoimmune-Related Diabetic Kidney Disease, Early-Onset Diabetic Kidney Disease
2) By Type 2 Diabetes: Obesity-Related Diabetic Kidney Disease, Late-Onset Diabetic Kidney Disease
Pre-Book The Diabetic Kidney Disease Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Diabetic Kidney Disease Market Landscape?
The trend of adopting latest technologies in the diabetic kidney disease market is increasingly getting popular among companies. They leverage these advancements to maintain their standing in the market. In an example from August 2022, a healthcare and diagnostics firm based in the US called Bloom Diagnostics, rolled out a new tool named Bloom Kidney Test that can assimilate with the Bloom Smart System. This Kidney Test tool by Bloom is designed to evaluate kidney health by monitoring the cystatin C levels, a significant marker of kidney function. This system categories the kidney's function into three stages: normal, mildly decreased, and decreased. The Bloom Smart System harmonizes test outcomes with other critical health data such as patient's medical history, lifestyle, and symptoms using AI technology and cloud-based algorithms.
Who Are the Key Players In The Diabetic Kidney Disease Market?
Major companies operating in the diabetic kidney disease market include:
• AstraZeneca plc
• Pfizer Inc.
• Novartis AG
• Bayer AG
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Fresenius SE & Co. KGaA
• F. Hoffmann-La Roche AG
• Abbott Laboratories
• Reata Pharmaceuticals Inc.
• Merck & Co.
• Mitsubishi Tanabe Pharma Corporation
• Johnson & Johnson pvt. Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Chugai Pharmaceutical Co. Ltd.
• Daiichi Sankyo Company Limited
What Are The Regional Insights Into The Diabetic Kidney Disease Market?
North America was the largest region in the diabetic kidney disease market in 2024. The regions covered in the diabetic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
